|
Chronic myelogenous (myeloid) leukemia (CML) therapy has greatly improved with the
introduction of tyrosine kinase inhibitors. However, advances are occurring so rapidly
in the diagnosis, treatment, and monitoring of patients with CML that clinicians
are challenged to maintain awareness of current treatment recommendations. Medical and community hematologists and oncologists, oncology nurses,
and primary care physicians who treat patients with CML need ongoing education regarding
therapeutic options and monitoring response. In Beyond Imatinib—Overcoming
Drug Resistance and Optimizing Therapy in CML, leading experts will
discuss improving outcomes for patients with CML through an understanding of the
leading causes of resistance to therapy, a consideration of agents that overcome
this resistance, and knowledge of the guidelines for monitoring disease response
to therapy.
|
The CML Reporters are interactive newspapers designed to keep you up-to-date on
issues and concerns surrounding CML.
Issue 2: Independent Coverage of a National
Hematology Meeting
Employing an interactive case-based model, these 3 workshops will
educate you about appropriate implementation of the existing guidelines and consideration
of new and emerging therapies.
Workshop 2: The Future of CML Therapy: Strategies Following Imatinib Failure or
Intolerance
Updated: November 5, 2008
Workshop 3: CML Treatment: Monitoring Patients and Managing Toxicities
Updated: November 5, 2008
|
